Revenio's First Combined Quarter: 48% Headline Growth, a Flat Core, and a Margin Squeeze It Can't Hide
One month of Visionix turns the top line into a step-function, but tariffs, memory costs and an €80m rights issue define the real story
REG1V.HE · Earnings Call · 2026-09-08
A historic quarter — and a deliberately un-historic one
Revenio Group's Q2 call was framed by CEO Jouni Toijala as a "historic moment," comparable in significance to the 2019 CenterVue deal. But the actual quarter is a paradox: the biggest revenue jump in the Finnish ophthalmic-device maker's history (net sales +48.1%, +50.7% currency-adjusted to roughly €39m for the quarter) comes almost entirely from consolidation mechanics — one single month of Visionix in the group numbers — while the legacy business went nowhere. “When looking as underlying business, our organic growth, that was more or less flat for the quarter.” — Jukka Kainulainen, CFO · 2026-09-08 The distinction matters. What management calls old Revenio grew in Q1 and flatlined in Q2, dragged by a softer market environment in APAC and a Middle East region Toijala tied directly to the Iran conflict. Europe was steady and the U.S. tonometer line performed, with the CEO insisting the Q3 start has "old Revenio back on the growth track." But the honest read is that the organic engine has cooled at exactly the moment the company took on acquisition debt. That debt is why the quarter's other headline exists: net debt of €238m and net-debt/EBITDA temporarily at 5.3x, against an €80m compulsory rights issue planned for H2 to repay the bridge-to-equity facility. Nordea is underwriting; the main owners (William Demant Invest plus the Visionix sellers, ~31%) have irrevocably committed to subscribe. The CFO expects leverage to fall to "closer to 3x" post-issue.The margin is where the real work is
Gross margin fell to 64.7% from 72.6% a year earlier — a fall the CFO split cleanly: roughly 2 percentage points of dilution from the lower-margin Visionix business, and about 5 points of deterioration inside old Revenio itself. The latter is where the fresh, non-boilerplate signal sits. Two forces are at work: tariffs, which barely touched last year's comparison because the company had pre-stocked inventory, and an inflationary squeeze on the component side. “We have been also seeing the increases on the component prices. Whether is it the memory, whether is it the CPU, whether is it the increased price on the gold, which is then used in the probes.” — Jouni Toijala, CEO · 2026-09-08 This is not a Revenio-only story. Multiple semiconductor and hardware reporters in the last five days flagged the same input-cost wave — Ambarella's memory cost inflation and Brady's memory-cost commentary echo Revenio's electronics squeeze. The difference is scale: Revenio is a €361m-cap medical-device firm absorbing chip inflation into a high-gross-margin product, and management's own admission is that the pre-tariff target of staying "constantly over 70%" is now "undoable." Instead they point to a 68–69% run-rate on the legacy side, further diluted by full-quarter Visionix from Q3.The tariff refund angle
Here the company lands squarely on one of the market's most crowded 2026 themes. Global editor keywords this quarter are dominated by tariff refunds — IEEPA recovery, net-tariff-refund benefits, refund-driven sales upside across dozens of callers. Revenio, which is currently paying tariffs, was asked outright whether it could claw money back. “Yeah, this is something we are looking after, the refunds from the tariffs. This is what we are working at the moment, actually.” — Jukka Kainulainen, CFO · 2026-09-08 That is a small but genuinely additive thread: a company on the wrong side of the tariff ledger signalling potential recovery, in the same quarter the broader tape began voting on refund beneficiaries. It is early and unquantified, but it is the kind of forward-looking hook that separates a real signal from boilerplate.AI screening: real progress, delayed ambitions
Strategically, the more consequential developments are in the commercial pipeline. Revenio secured the first FDA-cleared AI solution for its DRSplus retinal camera via partner iHealthScreen — a clearance Toijala called "extremely good news" expected to boost U.S. DRSplus sales. Meanwhile a new partnership with EyeCheq embeds DRSplus into an autonomous kiosk for holistic eye screening — a direct bet on the macro thesis that eye-health professionals are too scarce to diagnose a growing patient base. The irony is that the third-party clearance reduced internal urgency. Revenio's own iCare ILLUME AI submission, previously guided for clearance by H1 2027, now leans to Q3 2027, with a further FDA pre-submission added for safety. That is a two-to-four-quarter slip from a guided timeline — a quiet but meaningful negative buried in the Q&A. The integration itself, by contrast, is running ahead. Toijala said the company has "secured a bit ahead of time" the first €5m of run-rate savings against the EBITDA uplift target, with the combined U.S. sales team operational since August and management targeting a 25% margin for Visionix by 2029. Given Visionix's H1 revenue was flat year-on-year, that margin path depends entirely on synergy delivery rather than topline acceleration.The guidance game — and why it matters
The most telling exchange came from an analyst pushing back on the vague profitability wording. Guidance is net sales of €190–205m, with EBITDA "satisfactory" — a deliberate refusal to give a number, against last year's 24% adjusted EBIT and Q2's 17% adjusted EBITDA.Management took the feedback gracefully and pointed to the Capital Market Day on 15 September — a Capital Markets event where new strategy, combined go-to-market plans and fresh financial targets will land. For a company whose market cap sits near €361m and whose core business is flat, that event now carries more information value than the quarterly print itself. The bottom line: Revenio is a small-cap mid-integration with a genuine dual narrative — an accretive-in-theory acquisition paired with a margin problem that is part self-inflicted (Visionix dilution) and part externally imposed (tariffs, memory, gold). The flat organic core, the rights-issue dilution, and the slipped ILLUME timeline are all real negatives. But the on-plan synergies, the first FDA-cleared AI retinal label, the kiosk channel, and a possible tariff-refund tailwind are real optionality. September 15 will decide which narrative wins.I think if I were you, I would either not guide on it or I would just put a number out there... So we just get into this ridiculous game.